Suppr超能文献

蛋白酶体抑制剂在癌症治疗中的应用。

Proteasome inhibitors in cancer therapy.

机构信息

Centre for Cancer Research and Cell Biology, Queen's University Belfast, Ground Floor, 97 Lisburn Road, Belfast, Northern Ireland, BT9 7BL.

出版信息

J Cell Commun Signal. 2011 Jun;5(2):101-10. doi: 10.1007/s12079-011-0121-7. Epub 2011 Jan 31.

Abstract

The ubiquitin proteasome pathway plays a critical role in regulating many processes in the cell which are important for tumour cell growth and survival. Inhibition of proteasome function has emerged as a powerful strategy for anti-cancer therapy. Clinical validation of the proteasome as a therapeutic target was achieved with bortezomib and has prompted the development of a second generation of proteasome inhibitors with improved pharmacological properties. This review summarises the main mechanisms of action of proteasome inhibitors in cancer, the development of proteasome inhibitors as therapeutic agents and the properties and progress of next generation proteasome inhibitors in the clinic.

摘要

泛素蛋白酶体途径在调节细胞中的许多过程中起着关键作用,这些过程对肿瘤细胞的生长和存活很重要。抑制蛋白酶体的功能已成为抗癌治疗的一种有效策略。硼替佐米的临床验证了蛋白酶体作为治疗靶点,并促使开发了具有改善的药理学特性的第二代蛋白酶体抑制剂。本文综述了蛋白酶体抑制剂在癌症中的主要作用机制、蛋白酶体抑制剂作为治疗剂的发展以及下一代蛋白酶体抑制剂在临床中的特性和进展。

相似文献

1
Proteasome inhibitors in cancer therapy.
J Cell Commun Signal. 2011 Jun;5(2):101-10. doi: 10.1007/s12079-011-0121-7. Epub 2011 Jan 31.
2
Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
Front Biosci. 2008 May 1;13:4285-96. doi: 10.2741/3005.
3
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
J Cell Mol Med. 2014 Jun;18(6):947-61. doi: 10.1111/jcmm.12279. Epub 2014 Apr 8.
4
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
Adv Pharmacol. 2009;57:91-135. doi: 10.1016/S1054-3589(08)57003-7. Epub 2009 Nov 27.
5
Proteasome inhibitors in cancer therapy.
Curr Drug Targets. 2009 Oct;10(10):968-81. doi: 10.2174/138945009789577909.
6
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Endocr Relat Cancer. 2015 Feb;22(1):T1-17. doi: 10.1530/ERC-14-0005. Epub 2014 Mar 21.
7
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Curr Cancer Drug Targets. 2011 Mar;11(3):239-53. doi: 10.2174/156800911794519752.
8
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Drug Resist Updat. 2020 Jan;48:100663. doi: 10.1016/j.drup.2019.100663. Epub 2019 Nov 11.
9
Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Drug Resist Updat. 2015 Jul-Aug;21-22:20-9. doi: 10.1016/j.drup.2015.06.001. Epub 2015 Jul 6.
10
[Proteasome inhibitor].
Nihon Rinsho. 2014 Jun;72(6):1125-9.

引用本文的文献

1
Clinical use and toxicities of bortezomib in pediatric patients: a systematic review.
Front Pharmacol. 2025 Aug 6;16:1661493. doi: 10.3389/fphar.2025.1661493. eCollection 2025.
2
APG-115 synergizes with bortezomib to induce apoptosis in cervical cancer cells.
Anticancer Drugs. 2025 Sep 1;36(8):637-647. doi: 10.1097/CAD.0000000000001735. Epub 2025 Jun 3.
3
Ubiquitination in lipid metabolism reprogramming: implications for pediatric solid tumors.
Front Immunol. 2025 Apr 30;16:1554311. doi: 10.3389/fimmu.2025.1554311. eCollection 2025.
5
Harnessing p53 for targeted cancer therapy: new advances and future directions.
Transcription. 2025 Feb;16(1):3-46. doi: 10.1080/21541264.2025.2452711. Epub 2025 Mar 3.
6
Tumor microenvironment as a novel therapeutic target for lymphoid leukemias.
Ann Hematol. 2025 Mar;104(3):1367-1386. doi: 10.1007/s00277-025-06237-w. Epub 2025 Feb 25.
8
Exploring paraptosis as a therapeutic approach in cancer treatment.
J Biomed Sci. 2024 Nov 4;31(1):101. doi: 10.1186/s12929-024-01089-4.
9
O-GlcNAcylation of ribosome-associated proteins is concomitant with translational reprogramming during proteotoxic stress.
J Biol Chem. 2024 Nov;300(11):107877. doi: 10.1016/j.jbc.2024.107877. Epub 2024 Oct 10.
10
Melatonin for gastric cancer treatment: where do we stand?
Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb;398(2):1265-1282. doi: 10.1007/s00210-024-03451-7. Epub 2024 Sep 17.

本文引用的文献

1
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo.
Br J Haematol. 2011 Jan;152(2):155-63. doi: 10.1111/j.1365-2141.2010.08491.x. Epub 2010 Nov 29.
2
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.
Blood. 2010 Dec 2;116(23):4906-15. doi: 10.1182/blood-2010-04-276626. Epub 2010 Aug 30.
4
NFkappaB: a promising target for natural products in cancer chemoprevention.
Phytother Res. 2010 Jul;24(7):949-63. doi: 10.1002/ptr.3171.
5
Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition.
Cancer Sci. 2010 Jun;101(6):1403-8. doi: 10.1111/j.1349-7006.2010.01544.x. Epub 2010 Mar 15.
6
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
Br J Haematol. 2010 May;149(4):550-9. doi: 10.1111/j.1365-2141.2010.08144.x. Epub 2010 Mar 12.
8
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Cancer Res. 2010 Mar 1;70(5):1970-80. doi: 10.1158/0008-5472.CAN-09-2766. Epub 2010 Feb 16.
10
A new target for proteasome inhibitors: FoxM1.
Expert Opin Investig Drugs. 2010 Feb;19(2):235-42. doi: 10.1517/13543780903563364.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验